Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation.
Coburn SB, Lang R, Zhang J, Palella FJ, Horberg MA, Castillo-Mancilla J, Gebo K, Galaviz KI, Gill MJ, Silverberg MJ, Hulgan T, Elion RA, Justice AC, Moore RD, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Coburn SB, et al. Among authors: elion ra. J Acquir Immune Defic Syndr. 2022 Dec 15;91(5):469-478. doi: 10.1097/QAI.0000000000003083. J Acquir Immune Defic Syndr. 2022. PMID: 36053091 Free PMC article.
Factors Associated with Intention to Initiate Pre-exposure Prophylaxis in Cisgender Women at High Behavioral Risk for HIV in Washington, D.C.
Scott RK, Hull SJ, Huang JC, Coleman M, Ye P, Lotke P, Beverley J, Moriarty P, Balaji D, Ward A, Holiday J, Brant AR, Cameron M, Elion R, Visconti A. Scott RK, et al. Among authors: elion r. Arch Sex Behav. 2022 Jul;51(5):2613-2624. doi: 10.1007/s10508-021-02274-4. Epub 2022 May 27. Arch Sex Behav. 2022. PMID: 35622077 Free PMC article.
Changes in weight and BMI with first-line doravirine-based therapy.
Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, Hwang C, Sklar P, Martin EA. Orkin C, et al. Among authors: elion r. AIDS. 2021 Jan 1;35(1):91-99. doi: 10.1097/QAD.0000000000002725. AIDS. 2021. PMID: 33048879 Free PMC article.
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Patel SV, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Patel SV, et al. Among authors: elion ra. PLoS One. 2020 Feb 13;15(2):e0228847. doi: 10.1371/journal.pone.0228847. eCollection 2020. PLoS One. 2020. PMID: 32053682 Free PMC article.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.
Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study.
El-Sadr WM, Beauchamp G, Hall HI, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell DJ; HPTN 065 Study. El-Sadr WM, et al. Among authors: elion ra. J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):300-303. doi: 10.1097/QAI.0000000000001927. J Acquir Immune Defic Syndr. 2019. PMID: 31194704 Free PMC article.
94 results